PAB 0.00% 0.7¢ patrys limited

2024 An Eventful Year, page-3

  1. 3,125 Posts.
    lightbulb Created with Sketch. 244
    "Maybe even this???"
    I couldn't open that link gassed but I think I got an idea of what it's about from the link. There does seem to be a lot of activity by the big pharmas in the ADC area.
    Not to be outdone by its Big Pharma peers, Johnson & Johnson has fattened up its antibody-drug conjugate (ADC) pipeline via the acquisition of Ambrx Biopharma for $2 billion.
    Link to the article below. I would be happy with a $2b offer for PAB. It would equate to a share price of around Ninety cents US -

    J&J beefs up ADC pipeline by acquiring Ambrx for $2B (fiercebiotech.com)

 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.